74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Glaukos Corp
Closed
SectorHealthcare
95.2 2.93
Overview
Share price change
24h
Min
91.15
Max
95.2
Income | -12M -34M |
|---|---|
Sales | 8.8M 105M |
EPS | -0.4 |
Profit margin | -31.83 |
Employees | 995 |
EBITDA | -12M -22M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +60.77% upside |
Next Earnings | 30 Apr 2025 |
|---|
Market Cap | -1.9B 5.2B |
|---|---|
Previous open | 92.27 |
Previous close | 95.2 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Glaukos Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Glaukos Corp Forecast
Price Target
By TipRanks
60.77% upside
12 Months Forecast
Average 148.89 USD 60.77%
High 176 USD
Low 110 USD
Based on 10 Wall Street analysts offering 12 month price targets forGlaukos Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
